Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.
